San Francisco, CA – July 17th, 2024 – BIOMAKERS, a Precision Medicine & Biotech Company that supports data-driven Drug Development globally, and TOPAZIUM, an AI-driven healthtech company specializing in drug discovery and human wellbeing, have announced the results of their innovative collaborative project. This partnership showcases the power of AI systems in leveraging real-world DNA…
The magazine Emprendedores has organised a second meeting to discuss the impact of artificial intelligence (AI) on business. The aim was for the meeting to be practical for all attendees, featuring use cases from entrepreneurs in various sectors of the economy who have been leveraging AI for years to make their organizations and solutions more…
On June 11, Topazium presented at Madrid Innovation Lab (MIL; https://milmadrid.es/) its project HealthGuard, winner of the challenge “Mechanisms for Predicting and Controlling Chronic Diseases” at the 2023 AI and Advanced Technologies Awards. After a few words of welcome, Patricia Sarasola, Head of the Innovation Department of the Madrid City Council, emphasized the accessibility of…
SkinGuard is a computer-vision smartphone-based application utilising cutting-edge machine learning technologies to identify malignant skin lesions with an accuracy above 96%. It was fully developed and implemented by Topazium and it is intended for easy detection of skin cancer like melanoma to help practitioners (especially GPs) identifying the disease in its early stage. SkinGuardTM focuses…
Background: The advent of drugs targeting the PD-1/PD-L1 axis has revolutionized NSCLC treatment. Although promising, individual responses to these therapies can vary among individuals, and research is ongoing to better understand the mechanisms involved in PD1/PD-L1 expression to optimize treatment protocols, and identify which patients are most likely to benefit from these therapies. In this…
Background: Predicting life expectancy in prostate cancer patients is particularly difficult as different clinical factors significantly influence clinical outcome. Here we have developed MOSPROC, a simplified mortality predictive score to identify prostate cancer patients at high risk of mortality. Methods: The training set (TRS) (n=2,035) included metastatic Castration Resistant PC (mCRPC) patients from 4 randomized…
In an era of technological uncertainty, artificial intelligence (AI) emerges as a revolutionary tool capable of transforming multiple sectors, including medicine. However, it is crucial to understand its role as a complement rather than a substitute for human intelligence and quality, while maintaining the legacy of the Hippocratic method. The era of Artificial Intelligence (AI)…
Two machine learning frameworks developed in Topazium, GFPrint™ and PredLung™, have been used to extract important information from cancer patients, in particular from lung cancer patients, that may serve to design better therapies, generate virtual biomarker signatures and predict patient outcomes. Three case studies are presented, focused on i) the discovery of potential novel targets…
Some analyses of last year’s progress in AI-powered drug discovery indicate that none of the molecules fully generated by artificial intelligence (AI) were taken from discovery through clinical development. Although AI has expedited the process of identifying drug targets and discovering novel molecules to interact with them, the outcomes of some clinical trials have been…
The increasing availability of massive genetic sequencing data in the clinical setting has triggered the need for appropriate tools to help fully exploit the wealth of information these data possess. GFPrint™ is a proprietary streaming algorithm designed to meet that need. By extracting the most relevant functional features, GFPrint™ transforms high-dimensional, noisy genetic sequencing data…